Clinical Trials
-
Principal Investigator:
Shepard D. Weiner, MDThe purpose of this study is to compare the effects of Aficamten and placebo on health status and exercise capacity in participants with non-obstructive hypertrophic cardiomyopathy (nHCM). Participation in this research will involve up to 13 visits to the study site. The research study will last between 46 weeks (10.5 months) to at most 82 weeks (19 months). This time estimate includes the screening period(up to 6 weeks) to evaluate if you can participate in the study, the treatment period (36 to 72 weeks), and the follow-up period (of 4 weeks after the last treatment). -
Principal Investigator:
Hirad Yarmohammadi, MDYou may want to join this study because your heart condition may respond to a device-based therapy called cardiac modulation therapy, CCM therapy, called the OPTIMIZER System. -
Principal Investigator:
Margaret B. McEntegart, MDThis is a prospective, randomized, multi-center, controlled post-market study. The ALL-RISE study is looking at Fractional flow reserve (FFR) which is a medical test that doctors use to check how narrow the heart arteries are and decide if a stent or other treatment is needed. It helps doctors determine if the blockage is causing significant reduction in blood flow and guides them in making better choices for how to treat patients. The goal is to see if an image-based software system called FFRangio can accurately measure blood pressure and flow through the arteries as compared to using a... -
Principal Investigator:
Keith Diaz, PhDU.S. Adults spend on average 11 to 12 hours a day in sedentary behavior. Daily sedentary behavior is strongly associated with risk of cardiovascular disease. The purpose of the BREAK II research study is to answer two questions: (1) How frequent should periods of prolonged sedentary time be interrupted? and (2) What is the appropriate duration or length of time of these breaks in sedentary time? If you are 18 years old or older and have no history of chronic diseases, and no physical disability preventing ability to walk and a non-smoker you may be eligible for this study. Participants will... -
Principal Investigator:
Gabriel Tal Sayer, MDThis is a prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Repair System in patients with heart failure and reduced ejection fraction (HFrEF). -
Principal Investigator:
Susheel Kumar Kodali, MDThis Early Feasibility Study (EFS) is looking at the investigative device called the Half Moon TMVrSystem to see if it is safe and effective in treating patients with severe, symptomatic mitral regurgitation, who are at high risk for conventional mitral valve surgery. The system is designed so that a catheter can gain access to the heart by way of a large artery in the leg or by a small surgical passage through the walls between the right and left chamber of the heart. The implant then anchors on the leaflets of the valve in a certain manner. The Transcatheter Mitral Valve Replacement system... -
Principal Investigator:
Michael B Collins, MDThis is a Prospective, multicenter, randomized, parallel-controlled, open-label two-arm trial with an adaptive design that will randomize about 1252 subjects at approximately 120 US and international centers. The study is looking to see if a device called the Impella device will improve the way the heart works as well as if health is improved as compared to what is currently used for patients with reduced left-sided heart function. Participants will be assigned by the flip of a coin to receive the Impella device, or assigned to receive standard of care treatment. Participants will have a... -
Principal Investigator:
Susheel Kumar Kodali, MDThis is a prospective, single-arm, multi-center, early feasibility study. This research study is for patients who have Tricuspid Regurgitation (TR), a condition that occurs when the three leaflets of the heart's tricuspid valve do not close properly causing blood to leak backward with each heartbeat. Since some of the blood leaks backward, the heart has to pump more blood with each beat to push the same amount of blood forward. The goal of this study is to evaluate the safety and performance of the Evoque system with Optimal Medical Therapy (OMT) compared to OMT alone in the treatment of... -
Principal Investigator:
Susheel Kumar Kodali, MDThis is a research study for patients who have Tricuspid Regurgitation (TR), a condition that occurs when the three leaflets of the heart's tricuspid valve do not close properly causing blood to leak backward with each heartbeat. Since some of the blood leaks backward, the heart has to pump more blood with each beat to push the same amount of blood forward. The goal of this study is to gain early clinical insight into how the Intrepid transcatheter tricuspid valve replacement (TTVR) system device performs. There is a need for alternative and less invasive treatment options to treat this... -
Principal Investigator:
Sanjum Sethi, MDThe purpose of this study is to determine whether treatment with anticoagulation medications incombination with the EkoSonicTM Endovascular device with a dose of a clot-dissolving drug(thrombolytic) can reduce the risk of death and other serious problems when compared to anticoagulation medication alone. Other measurements will be taken to observe your overall health and quality of life for one year after treatment.